Solid Biosciences Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Maury Raycroft, one of the biotech analysts at Jefferies. I would like to welcome Bo Cumbo, the CEO of Solid Biosciences. Thanks so much for joining us today, Bo.
Yeah. Thank you, Maury, and thank you, Jefferies, for the invitation.
We are going to do fireside chat format. Maybe for those who are new to the story, if you can give us a brief intro to Solid and what you see as the key differentiating features of your DMD and Friedreich's ataxia programs.
Yeah. Thank you once again. Solid Biosciences is a precision genetic medicine company. We focus on rare disease. Currently, we are in gene therapy in two indications, primary indications, which is Duchenne muscular dystrophy, as well as Friedreich's ataxia. Both products are in the clinic. Our first program for DMD is we have dosed 53 patients. We are getting ready to meet with the FDA this quarter to talk about accelerated approval pathway, and we have started a phase III. Our second program is for Friedreich's ataxia. We have dosed five patients with multiple other patients that are scheduled to be dosed this year. We are going to meet with the FDA somewhere right around Q1, Q2 to talk about a double-blind placebo control trial, registrational trial for that program as well. Really, the differentiating factor is the delivery. One is using a muscle-specific capsid that detargets the liver.
The other is using, for Friedreich's ataxia, it's using a dual route of administration with an MRI-guided technology going right to the dentate nucleus. Both programs, we are trying to realize the importance of delivery. One is being used systemically. The other is not only systemically, but also using technology to get to the heart of the matter, which is the dentate nucleus for Friedreich's ataxia.
Got it. Yeah, it's a good introduction. You mentioned the FDA meeting coming up here in late fourth quarter. Maybe talk about your preliminary dataset. You've described a range of potential outcomes from that meeting where FDA could request additional data to supporting a path toward filing. What are the key drivers that will determine outcomes from this meeting, and will it be based on maturity and consistency of the functional data, relationship between expression and function, number of patients, or something else?
Well, the answer's probably yes. It's going to be a whole host of things. As I mentioned before, we've dosed 53 patients over the course of about a year and a half or so. We have 53 patients' worth of safety data that we're going to be going in with. We also have about 12 or slightly more patients that have at least one year of functional data. Not going to discuss the data that we're going to present. We're going to present that to the FDA first, and then we're going to present it to all the investors as well as all the patients after we get the minutes back from the FDA. But we're going to go in with a, I think, a very comprehensive dataset. We've been doing this from day one, looking at all the biological correlates that I think everybody knows.
You've seen it in our decks, whether it's expression to CK, to titin, to looking at troponin and ejection fraction. So we'll have all this data. We've added in additional data points to round out our biological correlate data that no one else has seen yet. We're going to present that, and then we're going to look at functional data as well. Functional data consists of time to rise, 10-meter run/walk, NSAA, all the things that you would expect in Duchenne. But we also supplement this with a stride velocity 95 that moves away from human error or bias or coaching to help augment the data package. We'll present it to the FDA, hopefully have a very good and productive conversation, talk about next steps for accelerated approval, and then I'll notify the street of that outcome.
Got it. If FDA is directionally supportive of accelerated approval but wants more evidence, you have already got substantially more patient data maturing behind the initial package. What is your strategy to work with the FDA, and what are the most likely rate-limiting steps at this point? Will you have to wait for additional follow-up, or potentially demonstrate something on confirmatory study enrollment?
No, it is a great question. So one of the scenarios, the FDA, to your point, there is really three scenarios, right? There is one that says, "Okay, you have got enough data. Let us go," and you start filing. Second pathway could be, okay, to your point, to your question, just need more data because I am going in with about 12, slightly more, of one year worth of data, patients with one year of data. Third could be, you have no path, finish phase III. I do not believe that that is going to be the case because I do think that this is a, and the FDA has stated itself, Duchenne is a high unmet need. Clearly, we have not solved the Duchenne problem, and these patients need choice and better therapies.
So in your middle question here, what if they say, "You need more patient data?" Well, that is, I guess, in a really positive scenario for us because as I mentioned, we dosed 53 patients. We were actually, because of the safety, being so transparent about safety, you can actually go back and look at all our presentations over time and figure out exactly how many patients we have dosed and when. In January of 2026, this year, I think we had a press release right before the conference in San Francisco, and we announced that we had dosed roughly 30 patients at that time. So that means by the end of this year, we are going to have roughly 30 patients' worth of one-year data.
When you create these briefing books and data packages for the FDA, you really have to cut off the data about five months, six months ahead of the meeting, just so you can put together the package and put together the dossier and send it in. If we hold this meeting in the next I said we will hold this meeting this year, so that means it is coming up in the next six weeks, and we probably are not going to do it over Christmas. Then that means that I will have 30 patients' worth of data. We just do a new data cut, schedule a new meeting, provide the data, and have the meeting and have the discussion. So I think we are sitting in a really good scenario as a company, or good position as a company, in scenario one and two.
Obviously, let's hope that scenario three is not an option. I do not think it will be because these kids need something, the physicians need something, and it is still a high unmet need. I think we have a great program.
Makes sense. Your confirmatory phase III is progressing in parallel. What are key details you can share on where the status of the study will be when you have the Type C meeting, and how quickly do you think the study could reach a meaningful enrollment threshold? In your mind, what is meaningful?
Yeah. We have not discussed, we are not going to discuss how many patients we are dosing until we are fully enrolled. But what I have said publicly is that we really need to get Europe and some of the sites in the U.S. up and running, and that will happen late this quarter to early next quarter. What we currently have right now, we only have two countries, which is Canada and Australia. Enrollment is relatively slow because it is two countries. In the near future, we will have Spain, Italy, the U.K., Netherlands, France, as well as multiple sites in the U.S. At that point, enrollment should speed up pretty dramatically, especially ex-U.S. and Europe, because there is just no other program available. That is progressing nicely. We do expect those sites, those countries, and those sites to open up in the next quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
